Menu Search
Equities

Fresenius SE & Co KGaA

FREX:GER

Fresenius SE & Co KGaA

Actions
Health CareHealth Care Providers
  • Price (EUR)32.79
  • Today's Change0.58 / 1.80%
  • Shares traded1.19m
  • 1 Year change+18.72%
  • Beta1.0515
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy7
Outperform10
Hold3
Sell0
Strong Sell0

Share price forecast in EUR

The 17 analysts offering 12 month price targets for Fresenius SE & Co KGaA have a median target of 40.00, with a high estimate of 44.00 and a low estimate of 30.00. The median estimate represents a 21.99% increase from the last price of 32.79.
High34.2%44.00
Med22.0%40.00
Low-8.5%30.00

Dividends in EUR

Historical dividend information is not available for Fresenius SE & Co KGaA.
Div growth (TTM)-100.00%
More ▼

Earnings history & estimates in EUR

On Nov 06, 2024, Fresenius SE & Co KGaA reported 3rd quarter 2024 earnings of 0.69 per share. This result was in line with the consensus of the 5 analysts following the company and outperformed last year's 3rd quarter results by 1.41.
The next earnings announcement is expected on Mar 03, 2025.
Average growth rate-15.10%
Fresenius SE & Co KGaA reported annual 2023 losses of -1.05 per share on Feb 21, 2024.
Average growth rate-10.10%
More ▼

Revenue history & estimates in EUR

Fresenius SE & Co. KGaA had 3rd quarter 2024 revenues of 5.37bn. This bettered the 5.29bn consensus of the 10 analysts covering the company. This was 47.52% below the prior year's 3rd quarter results.
Average growth rate-0.66%
Fresenius SE & Co. KGaA had revenues for the full year 2023 of 22.30bn. This was 45.40% below the prior year's results.
Average growth rate-7.67%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.